Intraarterial Peptide Receptor Radionuclide Therapy Using 90Y-DOTATOC for Hepatic Metastases of Neuroendocrine Tumors

Conclusion: Our study found that administration of PRRT via the proper hepatic artery did not reproduce the increase in hepatic tumor uptake that was previously reported. In addition, the single treatment using 90Y-DOTATOC did not induce tumor shrinkage, indicating that more treatment cycles may be required. Possible safety concerns in patients with a high liver tumor burden should inform patient selection for future studies.

Source: Journal of Nuclear Medicine - January 19, 2021 Category: Nuclear Medicine Authors: Lawhn-Heath, C., Fidelman, N., Chee, B., Jivan, S., Armstrong, E., Zhang, L., Lindsay, S., Bergsland, E. K., Hope, T. A. Tags: Clinical Source Type: research